MedPath

Kashiv BioSciences, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

14

Active:1
Completed:7

Trial Phases

2 Phases

Phase 1:13
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials

Phase 1
13 (92.9%)
Phase 3
1 (7.1%)

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy Postmenopausal Women
Interventions
First Posted Date
2025-05-29
Last Posted Date
2025-05-29
Lead Sponsor
Kashiv BioSciences, LLC
Target Recruit Count
40
Registration Number
NCT06995482
Locations
🇺🇸

Floridian Clinical Research LLC, Miami Lakes, Florida, United States

🇮🇳

Synergen Bio Pvt. Ltd., Pune, Maharashtra, India

Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

Phase 1
Completed
Conditions
Rheumatoid Arthritis (RA
Interventions
First Posted Date
2025-04-15
Last Posted Date
2025-04-15
Lead Sponsor
Kashiv BioSciences, LLC
Target Recruit Count
300
Registration Number
NCT06929039
Locations
🇨🇦

Not Disclosed, Missisauga, Canada

A Open Label ,Randomized, Balanced, Two-treatment, Single Period, Parallel, Comparative Pharmacokinetic Study in Healthy Subjects

Phase 1
Recruiting
Conditions
Chronic Idiopathic Urticaria
Interventions
Device: ADL-018 Autoinjector
Drug: ADL-018 Injection
First Posted Date
2025-04-15
Last Posted Date
2025-04-15
Lead Sponsor
Kashiv BioSciences, LLC
Target Recruit Count
150
Registration Number
NCT06929052
Locations
🇨🇦

Not Disclosed, Missisauga, Canada

Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study

Phase 1
Active, not recruiting
Conditions
Febrile Neutropenia
Interventions
Device: TPI-120 with On body injector
Drug: Fylntera
First Posted Date
2025-04-09
Last Posted Date
2025-04-09
Lead Sponsor
Kashiv BioSciences, LLC
Target Recruit Count
180
Registration Number
NCT06918587
Locations
🇯🇴

Not Disclosed, Jordan, Jordan

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

Phase 1
Completed
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2023-10-10
Last Posted Date
2023-10-10
Lead Sponsor
Kashiv BioSciences, LLC
Target Recruit Count
48
Registration Number
NCT06074757
Locations
🇯🇴

Triumpharma Cro, Amman, Jordan

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.